Servier's $1.55B muscular dystrophy drug fails trial

Becker muscular dystrophy slowly wastes away a person's muscles. There is still no approved drug for it. Back in June, the French drugmaker Servier paid $1.55 billion upfront for a shot at changing that. On Tuesday, that bet came back with bad news. The drug, called sevasemten, failed to beat a placebo in its main 18-month trial. Patients taking it showed no real improvement in muscle function.

The trial measured a specific walking-and-movement test, called the North Star Ambulatory Assessment. Patients on sevasemten scored no better than patients on a placebo. That's a clean miss, not a mixed result open to interpretation. The drug had real promise going in. It also carried FDA designations meant to speed up rare-disease drugs, including Orphan Drug and Fast Track status. None of that changes what the data actually showed. Edgewise Therapeutics originally developed sevasemten. It had already sold the drug's future to Servier back in June. Patients and families who were counting on this specific trial are the ones actually living with the result.

Keep reading — what to watch

Is this the end of the road for sevasemten? Not necessarily. Servier hasn't said whether it will keep testing the drug for a related condition, Duchenne muscular dystrophy. That trial is still in an earlier stage. The bigger question is what this does to the rest of the muscular dystrophy pipeline. A $1.55 billion bet failing in a disease with zero approved drugs sends a signal. Every other company working on this disease is watching. It may mean investors get more cautious about funding the next attempt, right when patients can least afford a slowdown.